Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial).

MLA

Miguel Santin, et al. “Comparison of Three Short-Course Rifamycin-Based Regimens for the Prevention of Tuberculosis in Patients with End-Stage Kidney Disease: Study Protocol for a Randomised Clinical Trial (RIFAKiD-TB Trial).” PLoS ONE, vol. 17, no. 10, Jan. 2022, p. e0276387. EBSCOhost, https://doi.org/10.1371/journal.pone.0276387.

APA

Miguel Santin, Sandra Perez-Recio, Maria D Grijota, Luis Anibarro, Jose M Barcala, Maria L De Souza-Galvao, Paloma Gijon, Rafael Luque, Francesca Sanchez, & RIFAKiD team trial. (2022). Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial). PLoS ONE, 17(10), e0276387. https://doi.org/10.1371/journal.pone.0276387

Chicago

Miguel Santin, Sandra Perez-Recio, Maria D Grijota, Luis Anibarro, Jose M Barcala, Maria L De Souza-Galvao, Paloma Gijon, Rafael Luque, Francesca Sanchez, and RIFAKiD team trial. 2022. “Comparison of Three Short-Course Rifamycin-Based Regimens for the Prevention of Tuberculosis in Patients with End-Stage Kidney Disease: Study Protocol for a Randomised Clinical Trial (RIFAKiD-TB Trial).” PLoS ONE 17 (10): e0276387. doi:10.1371/journal.pone.0276387.